CORDLIFE GROUP LIMITED
(Company Registration No.: 200102883E)
(Registered in the Republic of Singapore)

REGULATORY UPDATE: RENEWAL OF LICENCES

---

1. Introduction

The Board of Directors ("**Board**") of Cordlife Group Limited (the "**Company**") refers to, *inter alia*:

(a) its announcement dated 14 January 2025 relating to, *inter alia*, the renewal by the Ministry of Health ("**MOH**") of the Company's cord blood banking service licence (the "**CBBS Licence**") and human tissue banking service licence for a period of one (1) year with effect from 14 January 2025;

(b) its announcement dated 1 October 2025 (the "**September 2025 MOH Notice Announcement**") relating to, *inter alia*, the receipt by the Company of a letter from the MOH of the Director-General of Health's intention to suspend the Company's CBBS Licence for a period of one (1) year (the "**September 2025 MOH Notice**");

(c) its announcement dated 6 October 2025 relating to, *inter alia*, the outcome of the Board's detailed assessment on the Company's ability to operate as a going concern;

(d) its announcement dated 13 October 2025 relating to, *inter alia*, the extension of time granted by the MOH to the Company to provide written representations in relation to the contents of the September 2025 MOH Notice as well as the Company's voluntary stoppage of collection, testing, processing and/or storage of new CBUs since 30 September 2025;

(e) its announcement dated 27 October 2025 relating to the Company's submission of its written representations to the Director-General of Health on 27 October 2025, in relation to the contents of the September 2025 MOH Notice;

(f) the press release issued on 26 November 2025 by MOH relating to the MOH issuing a notice of regulatory action to the Company to stop collecting, testing, processing and/or storing new cord blood with effect from 26 November 2025 ("**November 2025 Press Release**"); and

(g) its announcement dated 1 December 2025 relating to the November 2025 Press Release and the MOH's decision to modify the Company's CBBS Licence through the addition of new licencing conditions ("**December 2025 Announcement**").

Unless defined, all capitalised terms used and not defined in this announcement shall have the same meanings as defined in the September 2025 MOH Notice Announcement and December 2025 Announcement.

2. Renewal of CBBS Licence (with additional conditions) and Human Tissue Banking Service Licence

The Company wishes to update that as informed by MOH:

(a) the Company's CBBS Licence has been renewed for a period of one (1) year from 14 January 2026 to 13 January 2027 (both dates inclusive); and

(b) the Company's human tissue banking service licence has also been renewed for a period of two (2) years from 14 January 2026 to 13 January 2028.

In particular, the Company's CBBS Licence is renewed subject to the following licence conditions which are substantially the same as those imposed pursuant to MOH's decision to modify the

Company's CBBS Licence as stated in the December 2025 Announcement:

(A) the Company shall not collect, test, process and/or store CBUs from infant donors, including person appointed to provide the aforementioned services on behalf of the Company, for the duration of its CBBS Licence except within the permitted scope and subject to the conditions set out in Table 1 below:

Permitted Scope	**Conditions**
(a) storing existing CBUs; (b) facilitating the transfer of existing CBUs to another local or accredited overseas CBBS provider; (c) facilitating retrieval of existing CBUs for clinical purposes, such as transplant; and (d) disposing of existing CBUs where such disposal is instructed or authorised in writing by the client.	(a) the Company must ensure that storage conditions of all existing CBUs are appropriate and regularly monitored;
	(b) the Company may only facilitate transfer of existing CBUs to another local or accredited overseas CBBS provider, where such transfer is requested by the Company's clients in writing;
	(c) the Company may only facilitate retrieval of existing CBUs and perform any necessary pre-release testing when requested by its clients for clinical purposes, such as transplant. Pre-release post-thaw testing includes:[1] (i) Post-thaw viable CD34+ and CD45+ enumeration and viability test performed in-house; and (ii) CFU assay, HLA typing, and/or haemoglobinopathy, testing are performed by clinical laboratory services or cord blood banking services licensed under the Healthcare Services Act 2020 of Singapore, or accredited overseas laboratories. The Company is required to facilitate the transport of testing samples to the respective testing laboratories; and
	(d) the Company may only dispose of existing CBUs where instructed or authorised by the client in writing.

(B) the Company shall:

[1] This pre-release post-thaw testing requirement has been introduced as part of the licencing conditions for the renewal, and was not included to the licence conditions imposed pursuant to MOH's modification of the CBBS Licence, further details of which are set out in the December 2025 Announcement.

(i) replace the Company's clinical governance officer ("**CGO**"), and employ a suitably qualified CGO who meets the requirements in regulation 4 of the Healthcare Services (Cord Blood Banking Service) Regulations 2021 on a full time basis;

(ii) release stored CBUs for clinical use only after a suitably qualified haematologist has reviewed and assessed that the CBU is suitable for the intended clinical use;

(iii) retrospectively review all CBUs stored since the resumption of full service on 14 January 2025 against the Company's established policies and where warranted, investigate the cause for non-conformation and implement appropriate remedial actions. All CBUs collected since 14 January 2025, irrespective of whether they conform to the Company's policies and procedures, must be further reviewed by the new CGO for continued storage for clinical use;

(iv) disclose any non-conformance identified to the mother of the infant who shall be counselled by a haematologist on the implications of the non-conformance in clinical use. Accordingly, the Company shall respect and carry out the mother's decision on the disposition of the CBU;

(v) retrospectively review all laboratory activities since the resumption of full service on 14 January 2025 for non-conformance and where warranted, to identify the root cause and implement appropriate corrective and preventive measures. Such laboratory activities include but are not limited to, maintenance of instruments, equipment and facilities, temperature monitoring, materials and supplier management, quality assurance and quality control measures; and

(vi) ensure that all laboratory personnel are re-trained and implement an effective supervisory framework (including the execution of quality measures and proper documentation) to ensure compliance with the Company's policies and procedures.

The Company is committed to meeting all applicable regulatory requirements and compliance with the aforementioned licencing conditions by the MOH during this period.

3. Implications on the Company

Financial performance of the Group

As announced by the Company on 13 October 2025, the Company has voluntarily stopped the collection, testing, processing and/or storage of any new CBUs since 30 September 2025 (i.e. one (1) day after the September 2025 MOH Notice). As directed by the MOH under the new licencing conditions, the Company will also not collect, test, process or store any new CBUs until and unless directed by the MOH to do so. For the avoidance of doubt, these licencing conditions only relate to the Company's operations in Singapore. The Group's business activities in all other jurisdictions (namely, Malaysia, Hong Kong, India, Philippines, Indonesia, and Thailand) are in full operation and the licences maintained by the Group in those jurisdictions remain in full force and effect.

Due to the uncertainties faced by the Company in view of the licencing conditions set out in paragraph 2 above and pending the outcome of full investigations on the Additional Relevant Tank Test Results for the Remaining 3 Tanks, the Company is unable to assess the financial impact of the financial performance of the Group for the financial year ending 31 December 2026.

Company's ability to continue as a going concern

Shareholders are advised to refer to the Going Concern Announcement for, *inter alia*, the Board's assessment on the Company's ability to operate as a going concern, which incorporates an analysis comprising multiple scenarios for possible outcomes and tolerance levels in light of various key risks and uncertainties.

4. Cautionary Statement

This announcement is made based on information currently available to the Company and contains forward-looking statements regarding the Company's expected financial position and prospects. These forward-looking statements and other matters discussed in this announcement regarding matters that are not historical fact are only predictions, and are inherently subject to risk factors, uncertainties and assumptions (including those set out in paragraph 3 above). As such, the Company's actual results or performance may be materially different from any future results or performance expressed or implied by such forward-looking statements. No representation is made as to the actual financial position and/or results of the Company and/or its subsidiaries.

The Company will update its shareholders if there are any material developments in relation to the above, including any developments which result in any material deviation from the Board's assessment on the Company's ability to continue as a going concern, in accordance with the requirements of the SGX-ST listing rules.

In the meantime, shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company. They should consult their stockbrokers, bank managers, solicitors, or other professional advisers if they have any doubt about the action they should take.

By order of the Board

CORDLIFE GROUP LIMITED

Cheok Hui Yee
Goh Xun Er
Company Secretaries

14 January 2026